Baxter International to divest BioPharma Solutions business to Advent and Warburg Pincus for $4.2bn

The deal is expected to close in the second half of 2023.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this